MAUI Imaging, Inc.

Maui Imaging develops advanced imaging technologies, notably the MAUI K3900 system, which revolutionizes medical diagnostics by enabling imaging through barriers like bone and air, targeted for emergency and trauma settings. Founded in 2006, Maui Imaging is based in Sunnyvale, US, and specializes in medical imaging solutions. In May 2025, MAUI Imaging, Inc. raised USD 14.

68 million in series D funding led by new investor Acertara Acoustic Laboratories. The firm focuses on technological advancements in healthcare, with particular attention to military applications. Maui Imaging’s primary offering is its breakthrough imaging system, the MAUI K3900, which has received FDA clearance for medical use. This innovative device is designed to overcome the limitations of traditional ultrasound by enabling imaging through and around barriers such as bone, air, and metal.

The K3900 is particularly aimed at applications in neurology and trauma care, providing real-time diagnostic capabilities in environments where conventional imaging methods, such as CT scans, are not feasible. The technology is intended for use by healthcare professionals in interventional radiology, emergency medicine, and trauma settings. It has specific applications in military environments, with contracts established with the U. S.

Department of Defense to assess its utility in field conditions, particularly in remote or austere locations. Geographically, MAUI Imaging targets both civilian healthcare facilities and military installations, expanding its market reach globally. Maui Imaging’s business model includes partnerships with healthcare providers, hospitals, and military organizations, focusing on B2B transactions. The company generates revenue through direct sales of its MAUI K3900 imaging system, complemented by potential service agreements for maintenance and training.

The flagship product is designed to support rapid diagnosis and treatment of traumatic injuries, fostering strong relationships within the emergency and trauma care sectors. While specific pricing plans for the MAUI K3900 are proprietary, the transaction structure typically involves direct sales to medical facilities and government contracts, thus facilitating a steady revenue stream. The company’s strategic partnerships with thought leaders and organizations further enhance its position in the market, allowing for ongoing revenue generation through collaborative projects and clinical use cases. Maui Imaging aims to enhance its product lineup by developing new imaging technologies, with plans to introduce upgraded versions of the MAUI K3900 in upcoming quarters.

The company will use May 2025 funding to support the manufacturing and commercialization of its Computed Echo Tomography-based imaging technology.